CHENGDU OLYMVAX BIOPHARMACEUTICALS revenue for the last year amounted to 496.00 M CNY, the most of which — 462.96 M CNY — came from its highest performing source at the moment, Adsorbed Tetanus Vaccine, the year earlier bringing 437.65 M CNY. The greatest contribution to the revenue figure was made by China — last year it brought CHENGDU OLYMVAX BIOPHARMACEUTICALS 496.12 M CNY, and the year before that — 547.48 M CNY.